Nicole Pezous

TL;DR: Blockade of IL-17A was ineffective and higher rates of adverse events were noted compared with placebo, and unfavourable responses on secukinumab were driven by patients with elevated inflammatory markers.

TL;DR: In healthy adults ≥ 60 years old, treatment with CNP520 was safe and well tolerated and resulted in robust and dose‐dependent Aβ reduction in the cerebrospinal fluid, and long‐term, pivotal studies with C NP520 have been initiated in the Generation Program.

TL;DR: This study investigated the hypothesis that AFQ056 (mavoglurant), a selective metabotropic glutamate receptor 5 antagonist, reduces chorea in Huntington's disease (HD).

TL;DR: Valsartan and enalapril provided comparable BP reductions and effective BP control and were well tolerated in hypertensive children aged 6–17 years.

TL;DR: In this article, a method for predicting therapeutic responsiveness of a subject suffering from cognitive impairments or dysfunctions, psychotic and/or neurodegenerative disorders to an alpha 7 nicotinic acetylcholine receptor activator treatment was proposed.